沙利度胺联合昂丹司琼预防肺癌化疗所致恶心呕吐的临床研究  

Clinical study of thalidomide combined with ondansetron in the prevention of nausea and vomiting in lung cancer patients with chemotherapy

作　　者：李敏[1] 高尔云[1] 崔方博 陈丽琼[1] 张丰林[1] 

机构地区：[1]马鞍山市人民医院肿瘤化疗科,安徽马鞍山243000

出　　处：《现代肿瘤医学》2016年第17期2719-2723,共5页Journal of Modern Oncology

基　　金：国家自然科学基金资助项目(编号:81502029)

摘　　要：目的：探讨沙利度胺联合昂丹司琼对肺癌患者接受含顺铂双药方案化疗所致恶心呕吐的有效性和安全性。方法：将2014年2月至2016年2月我院肿瘤科收治的60例肺癌患者随机分成试验组（30例）和对照组（30例）,均采用含顺铂25mg/m^2d1~3双药方案化疗。对照组用昂丹司琼注射液8mg qd d1~3化疗前30min静脉滴注,试验组在对照组基础上加用沙利度胺片100mg口服d1~5。结果：试验组和对照组急性恶心控制的有效率为90%vs 80%,完全缓解率为73%vs 67%,差异均无统计学意义（P均〉0.05）。试验组和对照组第2~5天延迟性恶心控制的有效率分别为：87%vs 53%（P=0.011）,80%vs 47%（P=0.016）,80%vs50%（P=0.030）,87%vs 74%（P=0.331）。试验组和对照组第2~5天延迟性恶心完全缓解率分别为：67%vs 37%（P=0.039）,57%vs 27%（P=0.036）,60%vs 23%（P=0.009）,67%vs 40%（P=0.070）。试验组和对照组急性呕吐控制的有效率为93%vs 90%,完全缓解率为84%vs 77%,差异均无统计学意义（P均〉0.05）。试验组和对照组第2~5天延迟性呕吐控制的有效率分别为：90%vs 73%（P=0.182）,83%vs70%（P=0.360）,87%vs 73%（P=0.333）,94%vs 80%（P=0.255）。试验组和对照组第2~5天延迟性呕吐完全缓解率分别为：76%vs 46%（P=0.034）,66%vs 33%（P=0.020）,70%vs 40%（P=0.038）,73%vs50%（P=0.110）。试验组和对照组的不良反应均可耐受,镇静、嗜睡、乏力、便秘、头痛和皮疹的发生率差异均无统计学意义（P均〉0.05）。结论：沙利度胺联合昂丹司琼能有效预防肺癌患者含顺铂双药化疗引起的恶心呕吐,能提高延迟性恶心呕吐的控制率,未增加特殊不良反应,安全性较好,是可供选择的止吐药物。Objective：To observe the effectiveness and safety of combination of thalidomide and ondansetronin to prevent the nausea and vomiting in lung cancer patients received containing two drug regimen of cisplatin chemotherapy.Methods：From February 2014 to February 2016,60 lung cancer patients were randomly divided into experimental group（ 30 cases） and control group（ 30 cases）.All the patients were scheduled to receive containing cisplatin 25 mg /m^2d1 ~ 3dual regimen chemotherapy.Patients in the control group were injected ondansetron 8mg qd d1 ~ 330 min before chemotherapy.In the experimental group,patients administed thalidomide tablets 100 mg oral d1 ~ 5extra.Results：The effective rate of acute nausea control in the experimental group and the control group was 90% vs 80%,the complete remission rate was 7 3 % vs 6 7 %,the difference was not statistically significant（ P〉0.05）.In the experimental group and control group,the efficiency of delayed nausea control in 2 ~ 5 days was 87% vs 53%（ P = 0.011）,80%vs 47%（ P = 0.016）,80% vs 50%（ P = 0.030）,87% vs 74%（ P = 0.331）.The complete remission rate of delayed nausea control in 2 ~ 5 days was 67% vs 37%（ P = 0.039）,57% vs 27%（ P = 0.036）,60% vs 23%（ P = 0.009）,67% vs 40%（ P = 0.070）.The effective rate of acute vomiting control in the experimental group and the control group was 93% vs 90%,the complete remission rate was 84% vs 77%,the difference was not statistically significant（ P〉0.05）.In the experimental group and control group,the efficiency of delayed vomiting control in the 2 ~ 5 days was 90% vs 73%（ P = 0.182）,83% vs 70%（ P = 0.360）,87% vs 73%（ P = 0.333）,94% vs 80%（ P = 0.255）.The complete remission rate of delayed vomoting control in 2 ~ 5 days was 76% vs 46%（ P = 0.034）,66% vs 33%（ P = 0.020）,70% vs 40%（ P = 0.038）,73% vs 50%（ P = 0.110）.The adverse reactions in both groups were tolerable,sedation,drowsiness,fatigue,constipation,headache and skin rash were not statistically

关 键 词：沙利度胺 肺癌 化疗 恶心 呕吐 

分 类 号：R734.2[医药卫生—肿瘤]